ASND
Ascendis Pharma A/S
$194.86
-$1.56(-0.79%)
63
Overall
--
Value
63
Tech
--
Quality
Market Cap
$11.97B
Volume
165.72K
52W Range
$118.03 - $208.16
Target Price
$251.56
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | $13.3M | $7.0M | $7.8M | $51.2M | $266.7M | $363.6M | ||
| Total Revenue | $13.3M | $7.0M | $7.8M | $51.2M | $266.7M | $363.6M | ||
| COST OF GOODS SOLD | ||||||||
| Cost of Revenue | -- | $80.8M | $3.5M | $12.1M | $44.4M | $44.3M | ||
| GROSS PROFIT | ||||||||
| Gross Profit | $13.3M | $7.0M | $4.3M | $39.0M | $222.3M | $319.4M | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $240.1M | $418.4M | $456.0M | $600.9M | $677.9M | $598.1M | ||
| Research & Development | $191.6M | $260.9M | $295.9M | $379.6M | $413.5M | $307.0M | ||
| Research Expense | $191.6M | $260.9M | $295.9M | $379.6M | $413.5M | $307.0M | ||
| Selling, General & Administrative | $48.5M | $76.7M | $160.2M | $221.2M | $264.4M | $291.1M | ||
| Selling & Marketing Expenses | $48.5M | $76.7M | $160.2M | $221.2M | $264.4M | $291.1M | ||
| Salaries & Wages | $-90.9M | $-136.8M | $-178.4M | $-214.7M | -- | -- | ||
| Depreciation & Amortization | $-6.7M | $-9.4M | $-11.0M | $-11.7M | -- | -- | ||
| Depreciation & Amortization | $-6.7M | $80.8M | $-11.0M | $-11.7M | -- | -- | ||
| OPERATING INCOME | ||||||||
| Operating income | $-226.8M | $-411.5M | $-451.8M | $-561.8M | $-455.5M | $-278.8M | ||
| EBITDA | $-212.8M | $-411.7M | $-368.6M | $-590.5M | $-423.5M | $-282.6M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | $-1.2M | $-1.9M | $-3.9M | $-30.7M | $44.1M | $72.9M | ||
| Intinc | $17.8M | $1.8M | $59.7M | $52.2M | $31.5M | $25.6M | ||
| Net Non-Operating Interest Income/Expense | $17.8M | $1.8M | $59.7M | $52.2M | $-12.6M | $-74.4M | ||
| Other Income/Expense | $8.1M | $9.5M | $-15.9M | $68.2M | $18.4M | $20.1M | ||
| Other Special Charges | $234.0K | $219.0K | $3.9M | $-5.4M | -- | -- | ||
| SPECIAL ITEMS | ||||||||
| Special Income Charges | $-1.2M | -- | $-3.9M | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | $3.9M | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-219.5M | $-421.1M | $-384.0M | $-608.5M | $-442.4M | $-300.4M | ||
| Pre-Tax Income | $-218.3M | $-419.2M | $-380.1M | $-577.8M | $-486.5M | $-373.2M | ||
| INCOME TAX | ||||||||
| Tax Provision | $-234.0K | $-219.0K | $-367.0K | $5.4M | $7.3M | $4.8M | ||
| NET INCOME | ||||||||
| Net Income | $-218.1M | $-419.0M | $-379.7M | $-583.2M | $-493.8M | $-378.1M | ||
| Net Income (Continuing Operations) | $-218.1M | $-419.0M | $-379.7M | $-583.2M | $-493.8M | $-378.1M | ||
| Net Income (Discontinued Operations) | $-218.1M | $-419.0M | $-379.7M | $-583.2M | $-493.8M | $-378.1M | ||
| Net Income (Common Stockholders) | $-218.1M | $-419.0M | $-379.7M | $-583.2M | $-493.8M | $-378.1M | ||
| Normalized Income | -- | -- | -- | -- | $-357.6M | $-369.5M | ||
| TOTALS | ||||||||
| Total Expenses | $240.1M | $418.4M | $459.6M | $613.0M | $722.3M | $642.4M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $46.5M | $50.6M | $54.8M | $56.1M | $56.3M | $57.9M | ||
| Average Shares Outstanding (Diluted) | $46.5M | $50.6M | $54.8M | $56.1M | $56.3M | $57.9M | ||
| Shares Outstanding | $48.0M | $53.8M | $56.9M | $57.2M | $60.7M | $60.7M | ||
| Basic EPS | $-4.69 | $-8.28 | -- | -- | $-8.55 | $-6.53 | ||
| Basic EPS (Continuing Operations) | $-4.69 | $-8.28 | -- | -- | $-8.55 | $-6.53 | ||
| Diluted EPS | $-4.69 | $-8.28 | -- | -- | $-8.55 | $-6.53 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-8.55 | $-6.53 | ||
| OTHER METRICS | ||||||||
| Acquisition Expense | -- | -- | -- | $50.5M | -- | -- | ||
| Depletion | -- | $80.8M | -- | -- | -- | -- | ||
| Earnings from equity interest | $-8.1M | $-9.5M | $12.0M | $-17.7M | $-18.4M | $-20.1M | ||
| Earnings From Equity Interest Net Of Tax | $-8.1M | $-9.5M | $12.0M | $-17.7M | $-18.4M | $-20.1M | ||
| Fees | $2.7M | $2.6M | $2.4M | $2.5M | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | $44.1M | -- | ||
| Loss And Loss Adjustment Expected Incurred | $1.2M | -- | -- | -- | -- | -- | ||
| Marketing Expense | -- | -- | $3.9M | -- | -- | -- | ||
| Non Recurring Operation Expense | $1.2M | -- | -- | -- | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | $44.4M | $44.3M | ||
| Other Write Down | $1.2M | -- | -- | -- | -- | -- | ||
| Other Write Off | -- | -- | -- | $50.5M | -- | -- | ||
| Realized Capital Gain | -- | -- | $3.9M | -- | -- | -- | ||
| Selling Expense | $48.5M | $76.7M | $160.2M | $221.2M | -- | -- | ||
| Write Down | -- | -- | $3.9M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ASND | $194.86 | -0.8% | 165.72K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |